[1]
|
Ferraro, R., Agarwal, A., Martin-Macintosh, E.L., et al. (2015) MR Imaging and PET/CT in Diagnosis and Management of Multiple Myeloma. Radiographics, 35, 438-454. https://doi.org/10.1148/rg.352140112
|
[2]
|
Rajkumar, S.V. (2019) Multiple Myeloma: Every Year a New Standard? Hematological Oncology, 1, 62-65.
https://doi.org/10.1002/hon.2586
|
[3]
|
Caro, J., Braunstein, M., Williams, L., et al. (2022) Inflammation and Infec-tion in Plasma Cell Disorders: How Pathogens Shape the Fate of Patients. Leukemia, 36, 613-624. https://doi.org/10.1038/s41375-021-01506-9
|
[4]
|
Hillengass, J., Moulopoulos, L.A., Delorme, S., Koutoulidis, V., Mosebach, J., Hielscher, T., et al. (2017) Whole-Body Computed Tomography versus Conventional Skeletal Survey in Patients with Multiple Myeloma: A Study of the International Myeloma Working Group. Blood Cancer Journal, 7, e599. https://doi.org/10.1038/bcj.2017.78
|
[5]
|
Baur-Melnyk, A., Buhmann, S., Becker, C., et al. (2008) Whole-Body MRI versus Whole-Body MDCT for Staging of Multiple Myeloma. The American Journal of Roentgenology, 190, 1097-1104. https://doi.org/10.2214/AJR.07.2635
|
[6]
|
Dinter, D.J., Neff, W.K., Klaus, J., et al. (2009) Comparison of Whole-Body MR Imaging and Conventional X-Ray Examination in Patients with Multiple Myeloma and Implications for Therapy. Annals of Hematology, 88, 457-464.
https://doi.org/10.1007/s00277-008-0621-6
|
[7]
|
Matsue, K., Kobayashi, H., Matsue, Y., et al. (2018) Prognostic Significance of Bone Marrow Abnormalities in the Appendicular Skeleton of Patients with Multiple Myeloma. Blood Advances, 2, 1032-1039.
https://doi.org/10.1182/bloodadvances.2017014720
|
[8]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548.
|
[9]
|
Horger, M., Claussen, C.D., Bross-Bach, U., et al. (2005) Whole-Body Low-Dose Mul-tidetector Row-CT in the Diagnosis of Multiple Myeloma: An Alternative to Conventional Radiography. European Journal of Radiology, 54, 289-297. https://doi.org/10.1016/j.ejrad.2004.04.015
|
[10]
|
Dimopoulos, M.A., Hillengass, J., Usmani, S., et al. (2015) Role of Magnetic Resonance Imaging in the Management of Patients with Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 33, 657-664.
https://doi.org/10.1200/JCO.2014.57.9961
|
[11]
|
Megibow, A.J., Kambadakone, A. and Ananthakrishnan, L. (2018) Dual-Energy Computed Tomography: Image Acquisition, Processing, and Workflow. Radiologic Clinics of North Amer-ica, 56, 507-520.
https://doi.org/10.1016/j.rcl.2018.03.001
|
[12]
|
缪琪, 任克. 能谱CT在胰腺癌诊断和治疗中的应用进展[J]. 中国医学影像技术, 2016, 32(1): 142-145.
|
[13]
|
任占丽, 贺太平, 张喜荣, 等. 能谱CT多参数成像在鉴别肺癌病理类型中的价值[J]. 中国中西医结合影像学杂志, 2020, 18(5): 486-489.
|
[14]
|
李英豪, 彭新佳, 金晖, 等. 能谱CT最佳单能量图提高下肢动脉造影成像质量研究[J]. 介入放射学杂志, 2016, 25(11): 997-1001.
|
[15]
|
张进, 王艺婷, 石瑞, 等. 能谱CT定量参数鉴别脊柱肺癌骨转移瘤及骨髓瘤的研究[J]. 中国现代医生, 2017, 55(32): 113-116.
|
[16]
|
石义志, 杨明慧, 邱晓明, 柯耀. 宝石能谱CT成像对结直肠管状腺癌分化程度评估的应用价值[J]. 临床放射学杂志, 2017, 36(9): 1283-1287.
|
[17]
|
李靖, 高剑波, 王睿, 方梦捷, 张永磊, 黎海亮. 能谱CT碘基值预测及评估胃腺癌淋巴结转移的价值[J]. 临床放射学杂志, 2022, 41(6): 1083-1088.
|
[18]
|
Glazebrook, K.N., Doerge, S., Leng, S., et al. (2019) Ability of Dual Energy CT to Detect Silicone Gel Breast Implant Rupture and Nodal Silicone Spread. AJR The American Journal of Roentgenology, 212, 933-942.
https://doi.org/10.2214/AJR.18.20138
|
[19]
|
Hillengass, J., Fechtner, K., Weber, M.A., et al. (2010) Prognostic Sig-nificance of Focal Lesions in Whole Body Magnetic Resonance Imaging in Patients with Asymptomatic Multiple Mye-loma. Journal of Clinical Oncology, 28, 1606-1610. https://doi.org/10.1200/JCO.2009.25.5356
|
[20]
|
Ippolito, D., Besostri, V., Bonaffini, P.A., et al. (2013) Diagnostic Value of Whole-Body Low-Dose Computed Tomography (WBLDCT) in Bone Lesions Detection in Patients with Multiplemyeloma (MM). European Journal of Radiology, 82, 2322-2327. https://doi.org/10.1016/j.ejrad.2013.08.036
|
[21]
|
Dutoit, J.C., Vanderkerken, M.A., Anthonissen, J., Dochy, F. and Verstraete, K.L. (2014) The Diagnostic Value of SE MRI and DWI of the Spine in Patients with Mono-clonal Gammopathy of Undetermined Significance, Smouldering Myeloma and Multiple Myeloma. European Radiology, 24, 2754-2765. https://doi.org/10.1007/s00330-014-3324-5
|
[22]
|
Winfield, J.M., Poillucci, G., Blackledge, M.D., Collins, D.J., Shah, V., Tunariu, N., Kaiser, M.F. and Messiou, C. (2018) Apparent Diffusion Coefficient of Vertebral Haemangiomas Allows Differentiation from Malignant Focal Deposits in Whole-Body Diffusion-Weighted MRI. Euro-pean Radiology, 28, 1687-1691.
https://doi.org/10.1007/s00330-017-5079-2
|
[23]
|
Messiou, C. and Kaiser, M. (2015) Whole Body Diffusion Weighted MRI—A New View of Myeloma. British Journal of Haematology, 171, 29-37.
|
[24]
|
Burns, R., Mulé, S., Zerbib, P., Vignaud, A., Itti, E., Rahmouni, A. and Luciani, A. (2018) IVIM MRI and Bone Marrow. In: Le Bihan, D., Lima, M., Federau, C. and Sigmund, E.E., Eds., Intravoxel Incoherent Motion (IVIM) MRI, Jenny Stanford Publishing, New York, 359. https://doi.org/10.1201/9780429427275-18
|
[25]
|
Pawlyn, C., Fowkes, L., Otero, S., Jones, J.R., Boyd, K.D., Davies, F.E., Morgan, G.J., Collins, D.J., Sharma, B., Riddell, A., et al. (2016) Whole-Body Diffu-sion-Weighted MRI: A New Gold Standard for Assessing Disease Burden in Patients with Multiple Myeloma? Leuke-mia, 30, 1446-1448. https://doi.org/10.1038/leu.2015.338
|
[26]
|
Dutoit, J.C. and Verstraete, K.L. (2016) MRI in Multiple Myeloma: A Pictorial Review of Diagnostic and Post- Treatment Findings. Insights Imaging, 7, 553-569. https://doi.org/10.1007/s13244-016-0492-7
|
[27]
|
Zamagni, E. and Cavo, M. (2012) The Role of Imaging Tech-niques in the Management of Multiple Myeloma. British Journal of Haematology, 159, 499-513. https://doi.org/10.1111/bjh.12007
|
[28]
|
Zamagni, E., Nanni, C., Patriarca, F., et al. (2007) A Prospective Compari-son of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography, Magnetic Resonance Imaging and Whole-Body Planar Radiographs in the Assessment of Bone Disease in Newly Diagnosed Multiple Myeloma. Haematologica, 92, 50-55.
https://doi.org/10.3324/haematol.10554
|
[29]
|
Basha, M., Hamed, M., Refaat, R., et al. (2018) Diagnostic Perfor-mance of 18F-FDG PET/CT and Whole Body MRI before and Early after Treatment of Multiple Myeloma: A Prospective Comparative Study. Japanese Journal of Radiology, 36, 382-393. https://doi.org/10.1007/s11604-018-0738-z
|
[30]
|
Sachpekidis, C., Goldschmidt, H. and Dimitrakopoulou Strauss, A. (2020) Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. Molecules, 25, 134. https://doi.org/10.3390/molecules25010134
|
[31]
|
Zamagni, E., Patriarca, F., Nanni, C., et al. (2011) Prognostic Relevance of 18F-FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients Treated with Up-Front Autologous Transplantation. Blood, 118, 5989-5995.
https://doi.org/10.1182/blood-2011-06-361386
|
[32]
|
Nanni, C., Zamagni, E., Celli, M., et al. (2013) The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience with 77 Patients. Clinical Nuclear Medicine, 38, e74-e79. https://doi.org/10.1097/RLU.0b013e318266cee2
|
[33]
|
Shortt, C.P., Gleeson, T.G., Breen, K.A., et al. (2009) Whole-Body MRI versus PET in Assessment of Multiple Myeloma Disease Activity. AJR The American Journal of Roentgenology, 192, 980-986.
https://doi.org/10.2214/AJR.08.1633
|
[34]
|
Derlin, T., Peldschus, K., Münster, S., et al. (2013) Comparative Diag-nostic Performance of 18F-FDG PET/CT versus Whole-Body MRI for Determination of Remission Status in Multiple Myeloma after Stem Cell Transplantation. European Radiology, 23, 570-578. https://doi.org/10.1007/s00330-012-2600-5
|
[35]
|
Hillner, B.E., Siegel, B.A., Liu, D., Shields, A.F., Gareen, I.F., Hanna, L., et al. (2008) Impact of Positron Emission Tomography/Computed Tomography and Positron Emission To-mography (PET) Alone on Expected Management of Patients with Cancer: Initial Results from the National Oncologic PET Registry. Journal of Clinical Oncology, 26, 2155-2161. https://doi.org/10.1200/JCO.2007.14.5631
|